Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LOXO-338 |
Synonyms | |
Therapy Description |
LOXO-338 inhibits BCL2, potentially leading to inhibition of tumor cell proliferation and tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 1258). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LOXO-338 | LOXO338|LOXO 338 | BCL2 inhibitor 27 | LOXO-338 inhibits BCL2, potentially leading to inhibition of tumor cell proliferation and tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 1258). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05024045 | Phase I | LOXO-338 + Pirtobrutinib LOXO-338 | Study of Oral LOXO-338 in Patients With Advanced Blood Cancers | Active, not recruiting | USA | POL | ITA | FRA | 0 |